UPDATE: Cowen & Company Upgraded Ironwood Pharmaceuticals
October 24, 2013 at 15:14 PM EDT
Cowen & Company analyst Edward Nash upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) from Market Perform to Outperform and maintained a $14 PT. Nash noted that the strong early performance of Linzess indicates that it will be a hit. The analyst reported that prescriptions are above Takeda/Sucampo's Amitiza, and
